Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Antineoplastic Agents
  • Adenocarcinoma
  • Bronchial Neoplasms
  • Carcinoma
  • EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
  • EGFR L858R
  • Respiratory Tract Neoplasms
  • Carcinoma, Bronchogenic
  • Neoplasms
  • Neoplasms by Histologic Type
  • Respiratory Tract Disease
  • Carcinoma Non-small-cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • EGFR Activating Mutation
  • Neoplasms by Site
  • Protein Kinase Inhibitors
  • Thoracic Neoplasms
  • Neoplasms, Nerve Tissue
  • EGFR C797S
  • Lung Diseases
  • Lung Neoplasms
  • EGFR T790M
  • EGFR Exon 19 Deletion
  • EGFR Gene Mutation
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The study will include a dose-escalation portion in patients with EGFR-mutated NSCLC who have previously received at least 1 prior EGFR-targeted TKI, followed by expansion groups consisting of patients with tumors harboring specific mutation profiles: EGFR T790M and C797S mutation (Group 1); EGFR T7...

The study will include a dose-escalation portion in patients with EGFR-mutated NSCLC who have previously received at least 1 prior EGFR-targeted TKI, followed by expansion groups consisting of patients with tumors harboring specific mutation profiles: EGFR T790M and C797S mutation (Group 1); EGFR T790M but not C797S (Group 2); or EGFR C797S but not T790M (Group 3).

Tracking Information

NCT #
NCT04862780
Collaborators
Not Provided
Investigators
Not Provided